NSAID ulcers: Prevalence and prevention

Modern Rheumatology

Volumn 10, Issue 1, 2000, Pages 2-7

  Graham, D Y ^a  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Bleeding; Misoprostol; Nonsteroidal anti inflammatory drug; Omeprazole; Ulcers

Indexed keywords

EID: 0002059030     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/s101650070031     Document Type: Review

References (61)

1. Baum C, Kennedy DL, Forbes MB. Utilization of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1985; 28: 686 – 92.
2. Anti-arthritic medication usage: United States, 1991. Stat Bull Metrop Insur Co. 1992; 73: 25 – 34.
3. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340: 1888 – 99.
4. Fries JF. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Ftheumatol Suppl 1991; 28: 6 – 10.
5. Fries JF. Assessing and understanding patient risk. Scand J Ftheumatol Suppl 1992; 92: 21 – 4.
6. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A ran-domized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 241 – 9.
7. Griffin MR. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury. Am J Med 1998;104:235- 29S.
8. Agrawal N. Risk factors for gastrointestinal ulcers caused by non-steroidal anti-inflammatory drugs (NSAIDs) [published erratum appears in J Fam Pract 1991 Jul;33(1):161. J Fam Pract 1991; 32: 619 – 24.
9. Fries JF, Williams CA, Bloch DA, et al. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med 1991; 91: 213 – 22.
10. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991; 115: 787 – 96.
11. Shorr RI, Ray WA, Daugherty JR, et al. Concurrent use of nons-teroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med 1993; 153: 1665 – 70.
12. Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleed-ing and perforation associated with individual non-steroidal anti-inflammatory drugs [published erratum appears in Lancet 1994 Apr 23;343(8904):1048]. Lancet 1994; 343: 769 – 72.
13. Griffin MR, Piper JM, Daugherty JR, et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991; 114: 257 – 63.
14. Garcia Rodriguez LA, Walker AM, Perez Gutthann S. Nonsteroi-dal antiinflammatory drugs and gastrointestinal hospitalizations in Saskatchewan: a cohort study. Epidemiology 1992; 3: 337 – 42.
15. Lanza LL, Walker AM, Bortnichak EA, et al. Peptic ulcer and gastrointestinal hemorrhage associated with nonsteroidal anti-inflammatory drug use in patients younger than 65 years. A large health maintenance organization cohort study. Arch Intern Med 1995; 155: 1371 – 7.
16. Henry D, Lim LL, Garcia Rodriguez LA, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996; 312: 1563 – 6.
17. Graham DY, Smith JL. Aspirin and the stomach. Ann Intern Med 1986; 104: 390 – 8.
18. Hochain P, Berkelmans I, Czernichow P, et al. Which patients taking non-aspirin non-steroidal anti-inflammatory drugs bleed? A case-control study. Eur J Gastroenterol Hepatol 1995; 7: 419 – 26.
19. Simon LS, Goodman T. NSAID-induced gastrointestinal toxicity. Bull Rheum Dis 1995; 44: 1 – 5.
20. Langman MJ, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs [published erratum appears in Lancet 1994 May 21;343(89041302]. Lancet 1994; 343: 1075 – 8.
21. Roderick PJ, Wilkes HC, Meade TW. The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. Br J Clin Pharmacol 1993; 35: 219 – 26.
22. Smalley WE, Ray WA, Daugherty JR, et al. Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. Am J Epidemiol 1995; 141: 539 – 45.
23. Graham DY. Prevention of gastroduodenal injury induced by chronic nonsteroidal antiinflammatory drug therapy. Gastro-enterology 1989; 96: 675 – 81.
24. Nobunga M, Graham DY, Saito T, et al. NSAID-induced gastrointestinal damage and its management. J Ftheumatol (Ryumachika) 1993; 9: 279 – 92.
25. Graham DY, Smith JL. Effects of aspirin and an aspirin-acetaminophen combination on the gastric mucosa in normal sub-jects. A double-blind endoscopic study. Gastroenterology 1985; 88: 1922 – 5.
26. Swift GL, Arnold J, Williams GT, et al. A comparison of upper gastrointestinal mucosal damage by standard and delayed-release indomethacin. Aliment Pharmacol Ther 1992; 6: 717 – 25.
27. Collins AJ, Davies J, Dixon AS. A prospective endoscopic study of the effect of Orudis and Oruvail on the upper gastrointestinal tract, in patients with osteoarthritis. Br J Ftheumatol 1988; 27: 106 – 109.
28. Graham DY. Clinical aspects of the protective effects of prostag-landins on non-steroidal anti-inflammatory drug-associated mucosal injury. In: Domschke W, Dannann HG, Peskar BM, et al. editors. Prostaglandins and leukotrienes in gastrointestinal dis-eases. Berlin: Springer-Verlag; 1988. p. 161 – 7.
29. Cooper SA. New peripherally acting oral analgesic agents. Annu Rev Pharmacol Toxicol 1983; 23: 617 – 47.
30. Brogden RN, Heel RC, Speight TM, et al. Piroxicam: a review of its pharmacological properties and therapeutic efficacy. Drugs 1981; 22: 165 – 87.
31. Trewin VF, Lawrence CJ, Rae SA, et al. Development and use of a gastropathy index for ranking the safety of non-steroidal anti-inflammatory drugs in the elderly. J Chin Pharm Ther 1994; 19: 209 – 14.
32. Henry D, Dobson A, Turner C. Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs. Gastroenterology 1993; 105: 1078 – 88.
33. LeLorier J. Patterns of prescription of nonsteroidal antiinflam-matory drugs and gastroprotective agents. J Ftheumatol Suppl 1995; 43: 26 – 7.
34. Agrawal NM, Aziz K. Prevention of gastrointestinal complications associated with nonsteroidal antiinflammatory drugs. J Ftheumatol Suppl 1998; 51: 17 – 20.
35. Graham DY. Nonsteroidal anti-inflammatory drugs, Helicobacter pylori, and ulcers: where we stand. Am J Gastroenterol 1996; 91: 2080 – 6.
36. Raskin JB, White RH, Jaszewski R, et al. Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: a prospec-tive, double-blind, multicenter study. Am J Gastroenterol 1996; 91: 223 – 7.
37. Agrawal NM, Roth S, Graham DY, et al. Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer. A randomized, controlled trial. Ann Intern Med 1991; 115: 195 – 200.
38. Singh G, Ramey DR, Morfeld D, et al. Gastrointestinal tract com-plications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med 1996; 156: 1530 – 6.
39. Gunshefski L, Flancbaum L, Brolin RE, et al. Changing patterns in perforated peptic ulcer disease. Am Surg 1990; 56: 270 – 4.
40. Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the pre-vention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 1996; 334: 1435 – 9.
41. Hudson N, Taha AS, Russell RI, et al. Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration. Gastroenterology 1997; 112: 1817 – 22.
42. NSAIDs and peptic ulcers [letter]. BMJ 1990; 300: 814 – 16.
43. Graham DY. High-dose famotidine for prevention of NSAID ulcers? Gastroenterology 1997; 112: 2143 – 5.
44. Yeomans ND, Tulassay Z, Juhasz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid suppression trial: ranitidine versus omeprazole for NSAID-associated ulcer treatment (ASTRO-NAUT) study group. N Engl J Med 1998; 338: 719 – 26.
45. Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole com-pared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus misoprostol for NSAID-induced ulcer management (OMNIUM) study group. N Engl J Med 1998; 338: 727 – 34.
46. Raskin JB, White RH, Jackson JE, et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med 1995; 123: 344 – 50.
47. T., Greenhalgh, How to read a paper, The basics of evidence-based medicine London, BMJ Publishing Group, (1997)
48. Chan FK, Sung JJ, Chung SC, et al. Randomised trial of eradica-tion of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997; 350: 975 – 9.
49. Hawkey CJ, Tulassay Z, Szczepanski L, et al. Randomised con-trolled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter eradication for lesion prevention. Lancet 1998; 352: 1016 – 21.
50. Gutierrez O, Melo M, Segura AM, et al. Cure of Helicobacter pylori infection improves gastric acid secretion in patients with corpus gastritis. Scand J Gastroenterol 1997; 32: 664 – 8.
51. El-Omar EM, Oien K, El-Nujumi A, et al. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 1997; 113: 15 – 24.
52. Miehlke S, Hackelsberger A, Meining A, et al. Severe expression of corpus gastritis is characteristic in gastric cancer patients in-fected with Helicobacter pylori. Br J Cancer 1998; 78: 263 – 6.
53. Labenz J, Tillenburg B, Peitz U, et al. Helicobacter pylori aug-ments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology 1996; 110: 725 – 32.
54. Sipponen P, Stolte M. Clinical impact of routine biopsies of the gastric antrum and body. Endoscopy 1997; 29: 671 – 8.
55. Stolte M, Bethke B. Elimination of Helicobacter pylori under treat-ment with omeprazole. Z Gastroenterol 1990; 28: 271 – 4.
56. Klinkenberg-Knol EC, Festen HP, Jansen JB, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: effi-cacy and safety. Ann Intern Med 1994; 121: 161 – 7.
57. Lamberts R, Creutzfeldt W, Struber HG, et al. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology 1993; 104: 1356 – 70.
58. Meining A, Kiel G, Stolte M. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during and after 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease. Aliment Pharmacol Ther 1998;12: 735 – 40.
59. Meining A, Bosseckert H, Caspary WF, et al. H2-receptor antago-nists and antacids have an aggravating effect on Helicobacter pylori gastritis in duodenal ulcer patients. Aliment Pharmacol Ther 1997; 11: 729 – 34.
60. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gas-tritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996; 334: 1018 – 22.
61. Hawkey C, Kahan A, Steinbruck K, et al. Gastrointestinal toler-ability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA study group. meloxicam large-scale international study safety assessment. Br J Ftheumatol 1998; 37: 937 – 45.